Medical Device | April 01, 2024
MTD acquires Ypsomed's pen needle and BGM businesses
This acquisition enables MTD to open new, strategic markets
This acquisition enables MTD to open new, strategic markets
The company had earlier announced about the approval received from the MHRA for Liraglutide
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
To accelerate the development of next-generation radioconjugates to treat cancer
The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Subscribe To Our Newsletter & Stay Updated
